Literature DB >> 28092803

OX40: Structure and function - What questions remain?

Jane Willoughby1, Jordana Griffiths2, Ivo Tews3, Mark S Cragg4.   

Abstract

OX40 is a type 1 transmembrane glycoprotein, reported nearly 30 years ago as a cell surface antigen expressed on activated T cells. Since its discovery, it has been validated as a bone fide costimulatory molecule for T cells and member of the TNF receptor family. However, many questions still remain relating to its function on different T cell sub-sets and with recent interest in its utility as a target for antibody-mediated immunotherapy, there is a growing need to gain a better understanding of its biology. Here, we review the expression pattern of OX40 and its ligand, discuss the structure of the receptor:ligand interaction, the downstream signalling it can elicit, its function on different T cell subsets and how antibodies might engage with it to provide effective immunotherapy.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Immunotherapy; Monoclonal antibody; OX40; OX40L; Tnfr; Treg

Mesh:

Substances:

Year:  2017        PMID: 28092803     DOI: 10.1016/j.molimm.2017.01.006

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  44 in total

1.  Ways and waves of MALT1 paracaspase activation.

Authors:  Laura Israël; Frédéric Bornancin
Journal:  Cell Mol Immunol       Date:  2017-08-07       Impact factor: 11.530

Review 2.  Novel Targets for the Treatment of Melanoma.

Authors:  Lara Ambrosi; Shaheer Khan; Richard D Carvajal; Jessica Yang
Journal:  Curr Oncol Rep       Date:  2019-11-06       Impact factor: 5.075

Review 3.  Novel Immunotherapy Combinations.

Authors:  Babar Bashir; Melissa A Wilson
Journal:  Curr Oncol Rep       Date:  2019-11-06       Impact factor: 5.075

4.  Imaging activated T cells predicts response to cancer vaccines.

Authors:  Israt S Alam; Aaron T Mayer; Idit Sagiv-Barfi; Kezheng Wang; Ophir Vermesh; Debra K Czerwinski; Emily M Johnson; Michelle L James; Ronald Levy; Sanjiv S Gambhir
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

5.  Jagged1-expressing adenovirus-infected dendritic cells induce expansion of Foxp3+ regulatory T cells and alleviate T helper type 2-mediated allergic asthma in mice.

Authors:  Chu-Lun Lin; Huei-Mei Huang; Chia-Ling Hsieh; Chia-Kwung Fan; Yueh-Lun Lee
Journal:  Immunology       Date:  2018-11-29       Impact factor: 7.397

Review 6.  OX40 as a novel target for the reversal of immune escape in colorectal cancer.

Authors:  Lin-Hai Yan; Xiao-Liang Liu; Si-Si Mo; Di Zhang; Xian-Wei Mo; Wei-Zhong Tang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

7.  The In Vitro Impact of Glycyrrhizic Acid on CD4+ T Lymphocytes through OX40 Receptor in the Patients with Allergic Rhinitis.

Authors:  Saloomeh Fouladi; Mohsen Masjedi; Ramin Ghasemi; Mazdak G Hakemi; Nahid Eskandari
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

8.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

9.  OX40 expression in neutrophils promotes hepatic ischemia/reperfusion injury.

Authors:  Hua Jin; Chunpan Zhang; Chengyang Sun; Xinyan Zhao; Dan Tian; Wen Shi; Yue Tian; Kai Liu; Guangyong Sun; Hufeng Xu; Dong Zhang
Journal:  JCI Insight       Date:  2019-11-01

10.  Reversal of sepsis-induced T cell dysfunction: OX-40 to the rescue?

Authors:  Edward R Sherwood; David L Williams
Journal:  J Leukoc Biol       Date:  2020-09-29       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.